Aaron Hansen
Aaron Hansen
Princess Margaret - University Health Network
Потвърден имейл адрес: uhn.ca
Tumour heterogeneity in the clinic
PL Bedard, AR Hansen, MJ Ratain, LL Siu
Nature 501 (7467), 355-364, 2013
Refining American Joint Committee on Cancer/Union for International Cancer Control TNM stage and prognostic groups for human papillomavirus-related oropharyngeal carcinomas
SH Huang, W Xu, J Waldron, L Siu, X Shen, L Tong, J Ringash, A Bayley, ...
J Clin Oncol 33 (8), 836-845, 2015
Tumour-and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review
L Khoja, D Day, T Wei-Wu Chen, LL Siu, AR Hansen
Annals of Oncology 28 (10), 2377-2385, 2017
Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1–positive nasopharyngeal carcinoma: results of the KEYNOTE-028 study
C Hsu, SH Lee, S Ejadi, C Even, RB Cohen, C Le Tourneau, JM Mehnert, ...
Journal of Clinical Oncology 35 (36), 4050-4056, 2017
A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors
TW Chen, AR Razak, PL Bedard, LL Siu, AR Hansen
Annals of Oncology 26 (9), 1824-1829, 2015
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised …
B Burtness, KJ Harrington, R Greil, D Soulières, M Tahara, G de Castro Jr, ...
The Lancet 394 (10212), 1915-1928, 2019
Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial
TL Stockley, AM Oza, HK Berman, NB Leighl, JJ Knox, FA Shepherd, ...
Genome medicine 8 (1), 1-12, 2016
Tracking the dynamics of circulating tumour cell phenotypes using nanoparticle-mediated magnetic ranking
M Poudineh, PM Aldridge, S Ahmed, BJ Green, L Kermanshah, V Nguyen, ...
Nature nanotechnology 12 (3), 274-281, 2017
Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair–deficient cancer: Results from the phase II KEYNOTE-158 study
A Marabelle, DT Le, PA Ascierto, AM Di Giacomo, A De Jesus-Acosta, ...
Journal of Clinical Oncology 38 (1), 1-10, 2020
Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study
AR Hansen, C Massard, PA Ott, NB Haas, JS Lopez, S Ejadi, ...
Annals of Oncology 29 (8), 1807-1813, 2018
PD-L1 testing in cancer: challenges in companion diagnostic development
AR Hansen, LL Siu
JAMA oncology 2 (1), 15-16, 2016
A classification system for clinical relevance of somatic variants identified in molecular profiling of cancer
MA Sukhai, KJ Craddock, M Thomas, AR Hansen, T Zhang, L Siu, ...
Genetics in Medicine 18 (2), 128-136, 2016
Immune-related adverse events associated with immune checkpoint inhibitors
D Day, AR Hansen
BioDrugs 30 (6), 571-584, 2016
Early phase clinical trials to identify optimal dosing and safety
N Cook, AR Hansen, LL Siu, ARA Razak
Molecular oncology 9 (5), 997-1007, 2015
Pembrolizumab for patients with advanced prostate adenocarcinoma: preliminary results from the KEYNOTE-028 study
A Hansen, C Massard, PA Ott, N Haas, J Lopez, S Ejadi, J Wallmark, ...
Annals of Oncology 27 (suppl_6), 725PD, 2016
Epidermal growth factor receptor targeting in head and neck cancer: have we been just skimming the surface?
AR Hansen, LL Siu
Journal of clinical oncology 31 (11), 1381-1383, 2013
A phase Ib dose escalation study of the OX40 agonist MOXR0916 and the PD-L1 inhibitor atezolizumab in patients with advanced solid tumors.
JR Infante, AR Hansen, MJ Pishvaian, LQM Chow, GA McArthur, ...
Journal of Clinical Oncology 34 (15_suppl), 101-101, 2016
Phase 1 trial design: is 3+ 3 the best?
AR Hansen, DM Graham, GR Pond, LL Siu
Cancer control 21 (3), 200-208, 2014
Immuno-oncology trial endpoints: capturing clinically meaningful activity
V Anagnostou, M Yarchoan, AR Hansen, H Wang, F Verde, E Sharon, ...
Clinical Cancer Research 23 (17), 4959-4969, 2017
988pd clinical activity and safety of Medi4736, an anti-Pd-L1 antibody, in patients with head and neck cancer
M Fury, SI Ou, A Balmanoukian, A Hansen, E Massarelli, A Blake-Haskins, ...
Annals of Oncology 25 (suppl_4), iv341-iv341, 2014
Системата не може да изпълни операцията сега. Опитайте отново по-късно.
Статии 1–20